COVID-19 Treatment

A Phase 3, multicenter, randomized, double-blind, 48-week study of the clinical and antiviral effect of S 217622 compared with placebo in non-hospitalized high risk participants with COVID 19

Study Status: Recruitment started 

Related Stories